Editas Medicine (EDIT) Interest & Investment Income (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Interest & Investment Income of $1.8 million for Q3 2025, down 48.13% year-over-year from $3.5 million in Q3 2024, and down 12.27% quarter-over-quarter from $2.1 million in Q2 2025.
Editas Medicine (EDIT) Interest & Investment Income (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Interest & Investment Income for 11 consecutive years, with $1.8 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Interest & Investment Income fell 48.13% year-over-year to $1.8 million; the TTM figure through Sep 2025 stood at $7.8 million (down 56.38% YoY), while the FY2024 annual figure was $14.1 million, down 19.95% from the prior year.
- Interest & Investment Income declined to $1.8 million in Q3 2025 per EDIT's latest filing, from $2.1 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $5.1 million in Q3 2023 and bottomed at $134000.0 in Q1 2021.
- Historically, Interest & Investment Income has averaged $2.3 million across 5 years, with a median of $2.1 million in 2025.
- Annual changes were most pronounced in 2021 — Interest & Investment Income sank 91.4% — and 2022, when it jumped 1449.71%.
- Editas Medicine's Interest & Investment Income stood at $175000.0 in 2021, then surged by 1449.71% to $2.7 million in 2022, then surged by 88.13% to $5.1 million in 2023, then slumped by 76.46% to $1.2 million in 2024, then soared by 52.46% to $1.8 million in 2025.
- Business Quant data shows EDIT's Interest & Investment Income at $1.8 million in Q3 2025, $2.1 million in Q2 2025, and $2.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 2.09 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 5.04 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 3.81 Mn |
| Mar 31, 2023 | 3.51 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 546,000.00 |
| Mar 31, 2022 | 469,000.00 |
| Dec 31, 2021 | 175,000.00 |
| Sep 30, 2021 | 152,000.00 |
| Jun 30, 2021 | 146,000.00 |
| Mar 31, 2021 | 134,000.00 |
| Dec 31, 2020 | 228,000.00 |